Celldex in the News

• December 13, 2009Celldex Therapeutics Presents Positive Results from Phase 2 Study of the Antibody-Drug Conjugate (ADC) Product Candidate CDX-011 in Advanced Breast Cancer
  
• December 7, 2009Celldex Therapeutics to Present CDX-011 Clinical Data at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium
  
• November 5, 2009Celldex Therapeutics to Present at Merriman Curhan Ford's Investor Summit 2009
  
• November 4, 2009Celldex Therapeutics Reports Third Quarter and Nine Month 2009 Financial Results
  
• October 29, 2009Celldex Therapeutics Presents Positive Clinical Data from Phase 1 Studies of Antibody-based Cancer Vaccine Candidate, CDX-1307
  
• October 1, 2009Celldex Therapeutics Announces Completed Acquisition of CuraGen Corporation
  
• September 30, 2009Celldex and CuraGen Stockholders Approve Acquisition of CuraGen Corporation

Celldex Fact Sheet

Download the Celldex Fact Sheet (.pdf)

Adobe® Acrobat Reader required to download and view PDFs.

About Celldex

Celldex Therapeutics is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex’s immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.

APC Targeting Technology^TM

Featured Links

• SABCS 2009 Poster - A Phase 1/2 Study of CR011-vcMMAE (CDX-011), an Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Breast Cancer
• iSBTc 2009 Poster - A Clinical Study Combining Multiple Immune Modulators and an APC-Targeted hCG-β Vaccine (CDX-1307)
• Video Clip - Brain Cancer Breakthrough, CNBC, June 1, 2009
• ASCO 2009 Poster - Epidermal growth factor receptor variant III-targeted vaccine in GBM
• ASCO 2009 Presentation – Phase 1 clinical results of an APC-targeted hCG-β vaccine (CDX-1307) with TLR agonists
• Learn more about APC Technology - Celldex's proprietary technology platform uses fully human monoclonal antibodies administered directly to patients to target and stimulate dendritic cells and macrophages.